Tech

Scientists Oppose Approved Alzheimer’s Drug

Recently, there have been extremely critical developments regarding the Alzheimer’s drug Aduhelm, which has been approved by the US Food and Drug Administration (FDA). Three FDA advisor scientists, who found the FDA’s approval of the drug wrong, resigned from their duties on the commission.

The US Food and Drug Administration (FDA) has made a very important decision recently and for the first time in 18 years, to Alzheimer’s medicine had given consent. After the drug produced by the company named Biogen had a great impact all over the world and was welcomed by many people with great happiness, a very striking and annoying event took place.

Established to support the FDA’s Alzheimer’s treatment studies scientists on the independent commissionthe decision to approve the drug Biggest mistake ever made by the FDA says it is. After reviewing the initial clinical data presented in November, the independent commission 10 out of 11 scientists say the drug should not be approved one person voted undecided. However, after the drug was approved, scientists began to resign from their duties in the commission.

Not enough evidence, too many side effects;

Biogen Alzheimer's drug

According to the resigning scientists, it will support the claim that the drug can slow cognitive decline in people in the early stages of the disease. there is not enough evidence. This drug, which has a high price tag of 56 thousand dollars, is enough to be sold at such a price according to the explanations. not effective.

In addition, according to the scientists in the committee, Aduhelm’s brain swelling and celebral hemorrhage It has serious side effects such as, but all these were ignored by the FDA and the drug was approved. According to scientists who resigned from their duties on the committee, the approval of such an inadequate and invalid drug, paves the way for new treatment methods to be developed.

RELATED NEWS

TÜBİTAK President Announces the Future of Two Domestic Coronavirus Medicines

by Biogen in the coming weeks drug to be distributedIt seems that it will remain on the agenda for a long time, especially considering its serious side effects.

Source :
https://www.nytimes.com/2021/06/10/health/aduhelm-fda-resign-alzheimers.html